 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Myelodysplastic Syndromes
CC-1088
| Angiogenesis inhibitor |
Celgene |
II |
| Clofarex (clofarabine) |
Purine nucleoside |
Bioenvision |
II |
| Dacogen (decitabine) |
DNA methylation modulator |
SuperGen |
III |
| DN-101 (calcitriol) |
Vitamin D |
Aventis |
II |
| ELL-12 (ether lipid) |
Ether-based antineoplastic |
Elan |
II |
| Orathecin (rubitecan) |
Topoisomerase I inhibitor |
SuperGen |
II |
| Thalomid (thalidomide) |
Angiogenesis inhibitor |
Celgene |
III |
| Thymoglobulin (antithymocyte globulin) |
Thymoglobulin |
SangStat |
II |
| TLK199 |
Bone marrow stimulant |
Telik |
II |
| Vidaza (azacitidine) |
Demethylating agent |
Pharmion |
Approved May 2004 |
| VNP401010M (cloretazine) |
Sulfonamide alkylating agent |
Vion |
II |
|
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
